Sandu [SANDUPHQ] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison

Sandu Pharmaceuticals, Inc.

BSE
Loading...

Sun Pharma Advanced Research Company Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sandu Pharmaceuticals, Inc. wins in 15 metrics, Sun Pharma Advanced Research Company Ltd. wins in 3 metrics, with 0 ties. Sandu Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Sandu Pharmaceuticals, Inc. Sun Pharma Advanced Research Company Ltd. Better
P/E Ratio (TTM) 20.68 -13.65 Sandu Pharmaceuticals, Inc.
Price-to-Book Ratio 1.00 -13.55 Sandu Pharmaceuticals, Inc.
Debt-to-Equity Ratio 1.06 -1.21 Sandu Pharmaceuticals, Inc.
PEG Ratio 0.27 -11.15 Sandu Pharmaceuticals, Inc.
EV/EBITDA 14.48 -22.27 Sandu Pharmaceuticals, Inc.
Profit Margin (TTM) 3.06% -53.22% Sandu Pharmaceuticals, Inc.
Operating Margin (TTM) 4.66% -700.71% Sandu Pharmaceuticals, Inc.
EBITDA Margin (TTM) 4.66% N/A N/A
Return on Equity 3.69% 157.88% Sun Pharma Advanced Research Company Ltd.
Return on Assets (TTM) 2.78% -102.08% Sandu Pharmaceuticals, Inc.
Free Cash Flow (TTM) $104,000 $-3.71B Sandu Pharmaceuticals, Inc.
Dividend Yield 1.61% N/A N/A
1-Year Return -20.14% 14.56% Sun Pharma Advanced Research Company Ltd.
Price-to-Sales Ratio (TTM) 0.63 87.98 Sandu Pharmaceuticals, Inc.
Enterprise Value $388.60M $50.87B Sun Pharma Advanced Research Company Ltd.
EV/Revenue Ratio 0.58 95.73 Sandu Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 57.96% -59.53% Sandu Pharmaceuticals, Inc.
Revenue per Share (TTM) $69 $2 Sandu Pharmaceuticals, Inc.
Earnings per Share (Diluted) $2.11 $-8.25 Sandu Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.07 0.19 Sandu Pharmaceuticals, Inc.

Sandu Pharmaceuticals, Inc. vs Sun Pharma Advanced Research Company Ltd. Stock Performance Analysis

Loading Price Chart...

SANDUPHQ
SPARC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sandu Pharmaceuticals, Inc.2.37%-3.49%-0.93%23.23%7.80%12.40%
Sun Pharma Advanced Research Company Ltd.2.14%-5.81%49.25%68.87%37.58%54.41%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sandu Pharmaceuticals, Inc.-20.14%-27.30%3.19%44.33%226.85%236.00%
Sun Pharma Advanced Research Company Ltd.14.56%13.10%-5.14%-23.02%148.11%-27.03%

Performance & Financial Health Analysis: Sandu Pharmaceuticals, Inc. vs Sun Pharma Advanced Research Company Ltd.

MetricSANDUPHQSPARC
Market Information
Market Cap i₹421.61M₹46.75B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i7,6992,401,062
90 Day Avg. Volume i5,4312,083,443
Last Close₹43.60₹212.97
52 Week Range₹30.00 - ₹58.28₹108.00 - ₹248.75
% from 52W High-25.19%-14.38%
All-Time High₹86.00 (Apr 25, 2022)₹875.00 (Apr 24, 2006)
% from All-Time High-49.30%-75.66%
Growth Metrics
Quarterly Revenue Growth0.02%-0.43%
Quarterly Earnings Growth0.76%-0.43%
Financial Health
Profit Margin (TTM) i0.03%-0.53%
Operating Margin (TTM) i0.05%-7.01%
Return on Equity (TTM) i0.04%1.58%
Debt to Equity (MRQ) i1.06-1.21
Cash & Liquidity
Book Value per Share (MRQ)₹43.50₹-10.63
Cash per Share (MRQ)₹3.85₹0.03
Operating Cash Flow (TTM) i₹5.35M₹-3,484,287,000
Levered Free Cash Flow (TTM) i₹15.52M₹-3,425,094,000
Dividends
Last 12-Month Dividend Yield i1.61%N/A
Last 12-Month Dividend i₹0.80N/A

Valuation & Enterprise Metrics Analysis: Sandu Pharmaceuticals, Inc. vs Sun Pharma Advanced Research Company Ltd.

MetricSANDUPHQ (Apr 24, 2026)SPARC (Apr 22, 2026)
Price Ratios
P/E Ratio (TTM) i20.68-13.65
Forward P/E iN/A2.60
PEG Ratio i0.27-11.15
Price to Sales (TTM) i0.6387.98
Price to Book (MRQ) i1.00-13.55
Market Capitalization
Market Capitalization i₹421.61M₹46.75B
Enterprise Value i₹388.60M₹50.87B
Enterprise Value Metrics
Enterprise to Revenue i0.5895.73
Enterprise to EBITDA i14.48-22.27
Risk & Other Metrics
Beta i0.070.19
Book Value per Share (MRQ) i₹43.50₹-10.63

Financial Statements Comparison: Sandu Pharmaceuticals, Inc. vs Sun Pharma Advanced Research Company Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSANDUPHQ (2025)SPARC (2025)
Revenue/Sales i671.92M717.66M
Cost of Goods Sold i332.04M1.10B
COGS % of Revenue i49.4%153.2%
Gross Profit i339.88M-381.94M
Gross Margin i50.6%-53.2%
Research & Development i2.33MN/A
Operating Income (EBIT) i20.94M-3.34B
Operating Margin i3.1%-465.5%
EBITDA i29.26M-3.23B
EBITDA Margin i4.4%-450.0%
Pre-Tax Income i21.59M-3.43B
Pre-Tax Income % of Revenue i3.2%-477.6%
Income Tax i6.07M-2.72M
Income Tax % of Revenue i0.9%-0.4%
Net Income (Profit) i15.52M-3.43B
Profit Margin i2.3%-477.3%

Balance Sheet & Liquidity Metrics

MetricSANDUPHQ (2025)SPARC (2025)
Cash & Equivalents i13.04M19.64M
Total Current Assets i262.99M261.97M
Total Current Assets % of Revenue i39.1%36.5%
Total Current Liabilities i120.86M3.74B
Total Current Liabilities % of Revenue i18.0%521.5%
Long-Term Debt i4.19M1.07B
Long-Term Debt % of Revenue i0.6%149.0%
Total Shareholders Equity i420.17M-2.17B
Retained Earnings i95.24M-23.22B
Retained Earnings % of Revenue i14.2%-3,235.0%
Property, Plant & Equipment i7.46M178.02M

Cash Flow Statement Comparison

MetricSANDUPHQ (2025)SPARC (2025)
Operating Cash Flow i5.35M-3.48B
Operating Cash Flow % of Revenue i0.8%-485.5%
Capital Expenditures i-9.38M-97.45M
Free Cash Flow i104,000-3.71B
FCF Margin i0.0%-516.4%
Debt Repayment iN/A-3.69B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSANDUPHQSPARC
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i9.66M324.52M
Float Shares i3.21M91.32M
% Held by Insiders i65.51%72.96%
% Held by Institutions i0.00%2.56%
% Held by Public i34.49%24.48%

Dividend Analysis & Yield Comparison: Sandu Pharmaceuticals, Inc. vs Sun Pharma Advanced Research Company Ltd.

MetricSANDUPHQSPARC
Last 12-Month Dividend i₹0.80N/A
Last 12-Month Dividend Yield i1.61%N/A
3-Year Avg Annual Dividend i₹1.02N/A
3-Year Avg Dividend Yield i1.12%N/A
3-Year Total Dividends i₹3.05N/A
Ex-Dividend DateSep 19, 2024N/A